Even for busy doctors, nothing is as good as a rep – for getting pharma info #biopharma #companies

Posted On Jan 8 2018 by

#pharma info # Even for busy doctors, nothing is as good as a rep for getting pharma info If you’re a pharma sales rep, chances are, you’re walking through a fog of existential angst. If you’re not questioning your existence, worrying that you’ll be laid off, or wondering whether the doctors in your territory will stop seeing reps, you know other reps who are. All the surveys and studies–doctors like seeing reps, doctors prefer to read, doctors are unduly influenced, doctors aren’t, e-detailing will or won’t replace reps–probably don’t help, either. But you’ve probably been around long enough to have …


The right niche helping Tris grow as pharma industry consolidates #pharma #software

Posted On Jan 7 2018 by

#tris pharma # The right niche helping Tris grow as pharma industry consolidates By. August 23, 2013 at 3:00 AM


Alnylam Soars as Drugmakers Circle Rival Biotechnology Company #pharma #sales #jobs

Posted On Jan 4 2018 by

#biotechnology company # Alnylam Soars as Drugmakers Circle Rival Biotechnology Company Alnylam Pharmaceuticals Inc. rose as much as 12 percent, the most in more than a year, after Sanofi, which owns a stake in the company, accelerated its pursuit of another drugmaker as potential rivals circled. suggesting demand for biotechnology acquisitions may be picking up. Sanofi Chief Executive Officer Olivier Brandicourt proposed eight independent candidates to replace Medivation Inc.’s board after the sitting members spurned the French company’s takeover offer. Meanwhile, people familiar with the Medivation chase said Celgene Corp. and Gilead Sciences Inc. were both considering bids for the …


The right niche helping Tris grow as pharma industry consolidates #french #pharmaceutical #companies

Posted On Dec 25 2017 by

#tris pharma # The right niche helping Tris grow as pharma industry consolidates By. August 23, 2013 at 3:00 AM


The right niche helping Tris grow as pharma industry consolidates #boehringer #pharmaceuticals

Posted On Dec 8 2017 by

#tris pharma # The right niche helping Tris grow as pharma industry consolidates By. August 23, 2013 at 3:00 AM


Jazz Pharma basks in praise as it adds CNS drugs in Azur acquisition #pharma #services

Posted On Dec 5 2017 by

#azur pharma # Jazz Pharma basks in praise as it adds CNS drugs in Azur acquisition Occasionally cited as a potential takeover target, Jazz Pharmaceuticals ($JAZZ) is in the news this morning with a takeover of its own. The biotech says it has struck an all-stock deal to acquire Dublin, Ireland-based Azur Pharma, adding new CNS drugs to its list of approved drugs. Once the proposed deal goes through, the combined operation is expected to have $475 million in annual revenue. Jazz CEO Bruce Cozadd told analysts this morning that the developer–which ran into a regulatory rejection last year–has been …


REGENICS AS #pharmaceutical #research #companies

Posted On Nov 28 2017 by

#biotechnology companies # Board of directors Tore Heldrup Rasmussen. MBA, Founder, Chairman of the Board. Mr. Rasmussen has been heading up several successful biotechnology companies prior to co-founding Regenics. Mr. Rasmussen brings many years of experience in strategy development and consumer products, as a Partner in MarkUp Consulting in Oslo and through tenures with Procter & Gamble and Orkla Foods (Norway). Mr. Rasmussen has an MBA degree from the University of Michigan. Harald Nordal. MSc, MBA. Mr. Nordal serves on the Regenics Board of Directors and is the managing Director of Life Capitol AS, a Norwegian based holding company located …


Alnylam Soars as Drugmakers Circle Rival Biotechnology Company #elder #pharma

Posted On Nov 10 2017 by

#biotechnology company # Alnylam Soars as Drugmakers Circle Rival Biotechnology Company Alnylam Pharmaceuticals Inc. rose as much as 12 percent, the most in more than a year, after Sanofi, which owns a stake in the company, accelerated its pursuit of another drugmaker as potential rivals circled. suggesting demand for biotechnology acquisitions may be picking up. Sanofi Chief Executive Officer Olivier Brandicourt proposed eight independent candidates to replace Medivation Inc.’s board after the sitting members spurned the French company’s takeover offer. Meanwhile, people familiar with the Medivation chase said Celgene Corp. and Gilead Sciences Inc. were both considering bids for the …


Jazz Pharma basks in praise as it adds CNS drugs in Azur acquisition #pharma #gossip

Posted On Nov 10 2017 by

#azur pharma # Jazz Pharma basks in praise as it adds CNS drugs in Azur acquisition Occasionally cited as a potential takeover target, Jazz Pharmaceuticals ($JAZZ) is in the news this morning with a takeover of its own. The biotech says it has struck an all-stock deal to acquire Dublin, Ireland-based Azur Pharma, adding new CNS drugs to its list of approved drugs. Once the proposed deal goes through, the combined operation is expected to have $475 million in annual revenue. Jazz CEO Bruce Cozadd told analysts this morning that the developer–which ran into a regulatory rejection last year–has been …


Novartis pharma head leaves as drug maker splits operations #helvoet #pharma

Posted On Nov 8 2017 by

#novartis pharma # Novartis pharma head leaves as drug maker splits operations Underscoring its increasing emphasis on oncology, Novartis is splitting its prescription drug business into two organizations and hired Paul Hudson, who heads North American operations for AstraZeneca, to lead the pharmaceutical business. The newly created oncology unit, meanwhile, will be run by Bruno Strigini, who already runs the cancer-drug business. The move comes a year after Novartis purchased a portfolio of oncology medicines from GlaxoSmithKline as part of an asset swap. But Novartis is also contending with declining sales of its Gleevec cancer medicine, which has been a …